Compare AbCellera Biologics Inc (ABCL) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.93. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | QDTE | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $36.60 |
52-Week Low | $2.78 | $26.85 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
QDTE trades at $30.42, up 1.57% with a bearish technical signal from moving averages. The ETF generates weekly dividend income with recent payments ranging from $0.12 to $0.28 per share. Technical indicators show neutral oscillators but bearish momentum with key support at $29 and resistance at $31. Recent media coverage highlights QDTE's high distribution yield strategy through 0DTE covered call options.
The outlook remains cautious given bearish technical signals, though the high-yield distribution strategy appeals to income investors. Key risks include options strategy execution and market volatility affecting premium income. Analyst sentiment appears mixed with some highlighting competitive yield advantages while others note concentration risks in large-cap growth exposures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
